VORICONAZOLE ACTAVIS voriconazole 50mg tablet blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

voriconazole, Quantity: 50 mg

Commercializzato da:

Medis Pharma Pty Ltd

INN (Nome Internazionale):

Voriconazole

Forma farmaceutica:

Tablet, film coated

Composizione:

Excipient Ingredients: lactose monohydrate; magnesium stearate; povidone; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; macrogol 3350

Via di somministrazione:

Oral

Confezione:

50, 56, 100, 28, 20, 2, 14, 10, 30

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

VORICONAZOLE ACTAVIS is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation. This brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Dettagli prodotto:

Visual Identification: white, round biconvex tablets, debossed 'VC50' on one side and plain on the reverse; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2015-02-02